Core Laboratories NV (CLB)

Kwaku Temeng is set to resign from the Core Laboratories (CLB) board of directors, effective October 1, 2026. His resignation stems from disagreements with the board regarding strategic direction and certain governance practices. Temeng has served on the board for over five years, holding roles as Chairman of the Nominating Committee and a member of the Compensation Committee.

Core Laboratories (NYSE: CLB) director Kwaku Temeng is resigning from the Board, effective October 1, 2026, due to disagreements over the company's strategic direction and governance practices, including succession planning and research priorities. Temeng, who chaired the Nominating Committee and served on the Compensation Committee, verbally notified the Board on August 19, 2026, and confirmed his resignation by letter on August 25, 2026. The company acknowledged his five years of service while noting the internal board differences.

Heartland Advisors Inc. has acquired a significant new position in Core Laboratories Inc. (NYSE:CLB), purchasing 1,058,311 shares valued at approximately $12.3 million, representing a 2.31% stake in the company. This move comes as institutional investors now hold 97.81% of Core Laboratories' stock, and analysts have recently upgraded their ratings, setting a consensus "Moderate Buy" with a $21 target price. Despite a year-over-year revenue decline, the company surpassed quarterly EPS estimates and declared a $0.01 dividend.

Advisors Capital Management LLC has made a new investment of $2.77 million in Core Laboratories Inc. (NYSE:CLB), acquiring 237,398 shares during the second quarter. This move makes Advisors Capital Management LLC a significant institutional holder, owning 0.52% of the oil and gas company. Other institutional investors also adjusted their positions in Core Laboratories, which recently reported earnings that beat analyst estimates and declared a quarterly dividend.

Zacks Research has increased its Q4 2027 EPS forecast for Core Laboratories (NYSE:CLB) to $0.24, up from $0.23, and projected Q1 2028 EPS at $0.11. This positive revision follows Core Laboratories' recent quarterly earnings report, which saw the company beat EPS expectations ($0.11 vs. $0.09 consensus) despite a 4.3% year-over-year revenue decline. Analyst sentiment for CLB has shifted to a "Moderate Buy," with an average price target of $21.00, significantly higher than its recent opening price of $12.29, and insider buying by CEO Lawrence Bruno further underscores confidence in the stock.